12 Health Care Stocks Moving In Friday's After-Market Session

Gainers

• Adial Pharmaceuticals ADIL stock moved upwards by 23.2% to $4.2 during Friday's after-market session. The company's market cap stands at $5.1 million.
• Aytu BioPharma AYTU shares increased by 11.24% to $1.88. The market value of their outstanding shares is at $10.3 million.
• Timber Pharmaceuticals TMBR stock moved upwards by 9.85% to $1.56. The company's market cap stands at $4.7 million.
• Mainz Biomed MYNZ shares rose 9.24% to $3.19. The market value of their outstanding shares is at $49.8 million. The company's, Q2 earnings came out 3 days ago.
• Processa Pharma PCSA stock rose 7.73% to $0.39. The market value of their outstanding shares is at $9.6 million.
• AIM ImmunoTech AIM stock increased by 7.33% to $0.67. The company's market cap stands at $32.4 million. As per the press release, Q2 earnings came out 3 days ago.

Losers

• Assure Hldgs IONM stock declined by 10.4% to $0.37 during Friday's after-market session. Today's trading volume for this security ended up closing at 341.7K shares, which is 166.5 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $1.9 million. As per the news, the Q2 earnings report came out 4 days ago.
• T2 Biosystems TTOO shares decreased by 8.88% to $0.51. Today's trading volume for this security ended up closing at 19.5 million shares, which is 19.4 percent of its average volume over the last 100 days. The company's market cap stands at $170.2 million.
• Biote BTMD shares declined by 8.46% to $4.33. The company's market cap stands at $120.0 million.
• OpGen OPGN stock fell 8.19% to $0.18. The market value of their outstanding shares is at $1.6 million.
• Biophytis BPTS stock decreased by 6.85% to $1.36. The market value of their outstanding shares is at $7.3 million.
• NeuroBo Pharmaceuticals NRBO shares fell 6.61% to $0.56. The company's market cap stands at $21.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.